What Is Tissue Typing and How Does It Work?

Tissue typing is the process of identifying specific proteins on the surface of your cells so that doctors can determine how well a donor organ or stem cell donation will match a recipient’s immune system. These proteins belong to a family called the human leukocyte antigen (HLA) system, and they sit on chromosome 6, making up the most genetically variable region in the entire human genome.¹ The closer two people’s HLA profiles are, the less likely the recipient’s immune system is to attack a transplanted organ or donated cells. Getting this match right can mean the difference between a transplant that lasts decades and one that fails within months.

Why HLA Proteins Matter So Much

Your immune system needs a way to tell your own cells apart from foreign invaders. It does this largely through HLA molecules, which act as display platforms on the surface of nearly every cell in your body. These molecules hold small fragments of proteins and present them to passing immune cells. If the fragment looks normal, the immune system moves on. If it looks foreign, an attack is launched.²

There are two broad classes of HLA molecules. Class I molecules (HLA-A, HLA-B, and HLA-C) appear on almost all nucleated cells and flag threats to one branch of immune cells. Class II molecules (HLA-DR, HLA-DQ, and HLA-DP) appear mainly on specialized immune cells and communicate with a different branch. When you receive tissue from another person, the recipient’s immune system inspects the donor’s HLA molecules. If those molecules look sufficiently different, the immune system treats the transplanted tissue as a threat and mounts a rejection response. Tissue typing exists to predict and prevent that scenario.

What Makes HLA So Hard to Match

HLA genes are extraordinarily diverse. Thousands of different versions of each gene exist across the human population, and each person inherits one set from each parent. The result is that no two unrelated people are likely to share exactly the same HLA profile unless they happen to come from a population where certain combinations are more common. Even siblings have only about a one-in-four chance of being a full HLA match.

This extreme variation is not an accident. Research has found that the diversity of HLA class I genes across different populations correlates with local pathogen richness, particularly at the HLA-B gene.³ In other words, infectious diseases have been a powerful evolutionary force pushing human HLA genes to diversify. A population with a wider range of HLA types is better equipped to recognize a wider range of pathogens. That is great for species-level survival but creates a genuine challenge when you need to find a compatible tissue donor.

How Tissue Typing Is Performed

The methods used to identify a person’s HLA type have changed dramatically over the past half-century, moving from relatively crude cell-based assays to precise DNA-level analysis.

Serological Typing

The earliest approach, developed in the 1960s, involved mixing a patient’s white blood cells with known antibodies and watching whether the cells died. If a specific antibody killed the cells, it meant those cells carried the corresponding HLA molecule. This micro-lymphocyte cytotoxicity test became the standard for decades.⁴ Different cell types, including T cells, B cells, and monocytes, could be tested in parallel using a complement-dependent cytotoxicity assay.⁵ The method worked, but it had limitations. It could only distinguish between broad groups of HLA types and sometimes produced ambiguous results, because antibodies do not always react cleanly with just one target.

Molecular Typing

The arrival of DNA-based methods in the 1990s transformed the field. Two techniques became workhorses in tissue typing labs around the world: sequence-specific oligonucleotide (SSO) probes and sequence-specific primers (SSP). Both rely on amplifying HLA gene segments and then checking whether specific known sequences are present. These methods can produce results ranging from a broad grouping to a precise allele-level identification, depending on how many probes or primers are used.⁶ They can also work with DNA from sources beyond blood, including cheek swabs and saliva samples.⁷

These approaches occasionally flag unusual reaction patterns that turn out to be previously unknown HLA variants.⁸ When that happens, sequencing-based typing steps in to read the gene letter by letter and resolve the ambiguity.

Next-Generation Sequencing

The latest leap forward uses next-generation sequencing to read entire HLA gene regions in one pass. Algorithms like HLA-HD map sequencing reads against a comprehensive dictionary of known HLA alleles and can determine a person’s type with six-digit precision, meaning they can distinguish between alleles that differ by just a single DNA position. Studies have shown this approach to be more accurate than conventional molecular typing methods.⁹ This level of resolution matters most in stem cell transplantation, where even tiny mismatches can trigger serious complications.

Crossmatching and Antibody Screening

Knowing a donor’s and recipient’s HLA types is only half the picture. Even when the types look compatible on paper, the recipient may already have antibodies against certain donor HLA molecules, formed through previous transplants, blood transfusions, or pregnancies. These preformed antibodies can cause immediate, catastrophic rejection. The crossmatch test catches this by mixing donor cells with recipient serum and checking for a reaction.

The traditional complement-dependent cytotoxicity crossmatch has been supplemented by flow cytometry crossmatching, which is far more sensitive. The use of increasingly sensitive crossmatch tests has nearly eliminated hyperacute rejection, the most dramatic and immediate form of graft failure.¹⁰ Each approach has trade-offs, though. The older cytotoxicity crossmatch is less sensitive, while the flow cytometry version picks up antibodies that may not actually cause graft damage, sometimes making it hard to tell which positive results are clinically meaningful.¹¹

Labs also screen recipient serum against panels of beads coated with individual HLA molecules. These single-antigen bead assays can pinpoint exactly which HLA antibodies a patient carries, helping transplant teams decide which donors to avoid. The technique has become essential for highly sensitized patients who have antibodies against many HLA types, but it can sometimes detect antibodies at levels too low to cause clinical harm, producing results that need careful interpretation.¹²

Virtual Crossmatching

Performing a physical crossmatch takes time, and for organs like hearts and lungs that cannot wait long outside the body, every hour counts. Virtual crossmatching offers a shortcut. Instead of mixing actual cells and serum, transplant teams compare a detailed record of the recipient’s known HLA antibodies against the donor’s HLA type. If the recipient has no antibodies against any of the donor’s HLA molecules, the virtual crossmatch is considered compatible.

Adopting virtual crossmatch protocols has significantly reduced cold ischemia time, the period an organ spends without blood flow between removal and transplantation, without increasing hyperacute rejection.¹³ In heart transplant patients, one analysis of over 250 crossmatch tests found that a compatible virtual crossmatch correctly predicted a compatible physical crossmatch about 92% of the time.¹⁴ That level of reliability means many transplants can now proceed on the basis of the virtual result alone, with a physical crossmatch done afterward as confirmation rather than a prerequisite.

How Matching Requirements Differ by Organ

Not every transplant demands the same degree of HLA matching. Kidney transplantation has historically benefited the most from close matching at the HLA-A, HLA-B, and HLA-DR loci. Better matches lead to longer-lasting grafts, and kidneys from fully matched donors consistently outperform those with mismatches.¹⁵

Heart and lung transplants present a practical problem. Donor organs deteriorate quickly and must be transplanted within hours, leaving little time for extensive matching. Studies have shown that matching at the HLA-A and HLA-DR loci does improve outcomes for heart transplants, with progressively better survival as more loci are matched.¹⁶ But the urgency of finding a size-appropriate organ for a critically ill patient usually takes priority over finding the best immunological match. Corneal grafts, on the other hand, rarely require HLA matching at all because the cornea lacks blood vessels under normal conditions, which limits immune cell access to the transplanted tissue.¹⁵

Stem cell transplantation is the most demanding. Donors and recipients are typically typed at high resolution for HLA-A, HLA-B, HLA-C, and HLA-DRB1.¹⁷ Even a single mismatch at certain loci significantly raises the risk of severe graft-versus-host disease, where the donor’s immune cells attack the recipient’s body. Mismatches at the HLA-C locus carry a particularly strong association with this complication.¹⁸

When a Perfect HLA Match Is Not Enough

Even fully HLA-matched transplants sometimes run into trouble. A significant share of complications in well-matched transplants is attributed to non-HLA histocompatibility systems, known as minor histocompatibility antigens.¹⁹ These are smaller protein differences encoded by genes scattered across the rest of the genome. Though each one individually has a small effect, collectively they can provoke immune responses.

Interestingly, studies of HLA-matched kidney transplants have found that mismatches for several well-characterized minor antigens did not significantly affect five-year graft survival on their own.²⁰ The picture remains unclear, partly because there are many such antigens and their cumulative effect is hard to measure. Researchers are also exploring whether structural-level matching, looking at the specific shapes on HLA molecules rather than just their gene names, could improve transplant outcomes further. Eplet-based matching, which focuses on the antibody-accessible patches on HLA proteins, has shown promise for reducing rejection across all three class II HLA loci.²¹

Tissue Typing Beyond Transplants

HLA typing has found an important role in pharmacogenomics, the study of how your genetic profile affects your response to drugs. The clearest example involves the HIV drug abacavir, which causes severe hypersensitivity reactions exclusively in people carrying the HLA-B*57:01 variant.²² Research has shown that abacavir binds within the groove of that particular HLA molecule and alters the set of self-peptides it displays, essentially tricking the immune system into attacking the patient’s own cells.²³ Today, HLA-B*57:01 screening is routine before prescribing abacavir, effectively preventing these reactions.²⁴ Similar associations between specific HLA types and drug reactions have been found for other medications, making HLA typing an increasingly practical tool in personalized medicine.

Monitoring After Transplant

Tissue typing does not end once the organ is in place. The recipient’s immune response can shift over time, sometimes developing new antibodies against the donor’s tissue months or years later. Traditionally, monitoring for rejection has relied on tissue biopsies, which are invasive and carry their own risks.

A newer approach measures donor-derived cell-free DNA circulating in the recipient’s blood. When transplanted cells are damaged or destroyed, they release fragments of their DNA into the bloodstream. Because the donor and recipient have different genetic profiles (determined, in part, through tissue typing), these donor fragments can be distinguished and quantified. Studies have found that donor-derived cell-free DNA levels correlate strongly with allograft rejection.²⁵ In kidney transplant recipients, levels below about 1% generally reflect the absence of active rejection, while levels above that threshold suggest rejection may be occurring.²⁶ The test has also been validated in heart transplant recipients, where elevated donor DNA drops after successful rejection treatment.²⁷ This kind of monitoring would not be possible without the genetic distinctiveness that tissue typing reveals in the first place.

HLA and Pregnancy

One of the more puzzling aspects of immunology is that a fetus, which carries HLA molecules inherited from the father, is not rejected by the mother’s immune system. The fetus is essentially a semi-foreign graft living inside the mother for nine months. Specialized regulatory immune cells in the uterine lining play a central role in maintaining this tolerance.²⁸ The placenta also limits which HLA molecules are expressed on fetal cells that contact maternal blood, reducing the chance of triggering an immune response.²⁹

Pregnancy does leave an immunological footprint, however. Exposure to the father’s HLA molecules can cause the mother to develop HLA antibodies. This is one reason women who have had multiple pregnancies are sometimes harder to match for transplants. Their immune systems have been “educated” against a wider range of HLA types, making the pool of compatible donors smaller.

Gene Editing and the Future of Compatibility

Researchers are exploring whether gene editing could sidestep the matching problem altogether. Using CRISPR-Cas9, scientists have knocked out HLA-A gene expression in cells, which could theoretically expand the pool of acceptable donors for stem cell transplants by reducing the number of alleles that need to match.³⁰

A more ambitious strategy involves engineering stem cells that retain only HLA-C while knocking out HLA-A and HLA-B. This approach preserves enough HLA on the cell surface to prevent natural killer cells from destroying them (since those cells attack targets that lack HLA entirely) while minimizing the markers that trigger conventional immune rejection. Researchers estimated that just 12 cell lines engineered this way, combined with HLA class II knockout, could be immunologically compatible with over 90% of the world’s population.³¹ If that estimate holds up in clinical settings, it would represent a fundamental shift. Instead of searching for a matching donor for each patient, you could draw from a small bank of universally compatible cells, potentially transforming regenerative medicine along with organ and tissue transplantation.